STAB1 and leukemia: By inhibiting CLEVER-1 in cell lines and patient cells ex vivo with bexmarilimab treatment as single-agent and in combination with azacitidine and venetoclax, we demonstrate changes in myeloid cell antigen presentating molecule expression and leukemia cell sensitivity to SoC drugs.